Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.
Bellone M, Pradelli L, Molica S, et al. Clin Outcomes Res CEOR 2021; 13: 661-71.
Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice.
Pradelli L, Sinigaglia T, Migliore A, et al. Ther Clin Risk Manag 2021; 17: 507-30.
Medium-Chain Triglyceride (MCT) Content of Adult Enteral Tube Feeding Formulas and Clinical Outcomes. A Systematic Review.
Muscaritoli M, Pradelli L. Front Nutr 2021; 8: 697529.
Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
Mangia PP, Gallo O, Ritrovato D, et al. Clin Drug Investig 2021; 41: 785-94.
Cost-Effectiveness of Parenteral Nutrition Containing ω-3 Fatty Acids in Hospitalized Adult Patients From 5 European Countries and the US.
Pradelli L, Klek S, Mayer K, et al. JPEN J Parenter Enteral Nutr 2021; 45: 999-1008.
Comparison of Consistency, Feasibility, and Convenience of a Novel Compact System for Assessing Lung Volumes and Carbon Monoxide Diffusing Capacity versus Whole Body Plethysmography.
Dal Negro RW, Turco P, Povero M. Clin Outcomes Res CEOR 2021; 13: 637-43.
Comparative Cost and Effectiveness of a New Algorithm for Early Lyme Disease Diagnosis: Evaluation in US, Germany, and Italy.
Pradelli L, Pinciroli M, Houshmand H, et al. Clin Outcomes Res CEOR 2021; 13: 437-51.
Assessing the Effect of Nutrition Therapy on Rehospitalization Rate in Malnourished Pediatric Patients With Chronic Diseases.
Lezo A, Povero M, Pradelli L, et al. JPEN J Parenter Enteral Nutr 2021; 45: 1400-1407.
Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy.
Povero M, Pradelli L, Serra A, et al. Farmeconomia Health Econ Ther Pathw 2021; 22.
[The Multidisciplinary Management of Type 2 Diabetes: an Integrated Care Model]
Berra CC, Pradelli L. Farmeconomia Health Econ Ther Pathw 2021; 22.
Gestione del paziente affetto da diabete mellito T2: la presa in carico ottimizzata
Celeste Berra C. C., Pradelli L. – Farmeconomia. Health economics and therapeutic pathways 2021; 22(S2): 1-16
The contribution of patients’ lung function to the inspiratory airflow rate achievable through a DPIs’ simulator reproducing different intrinsic resistance rates
Dal Negro R W, Turco P, Povero M. – Multidis Res Med 2021 Apr.15;16
Assessing the global usability of dry powder inhalers: analysis of six devices widely used for asthma
Dal Negro R W, Turco P, Povero M. – J Pulm Med Respir Res 2021
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Carpagnano GE, Resta E, Povero M, Pelaia C, D’Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro – Sci Rep. 2021 Mar
Preliminary cost-effectiveness and cost-utility analysis of cemiplimab in patients with advanced cutaneous squamous cell carcinoma in Italy
Ghetti G, D’Avella MC, Pradelli L. – Clinicoecon Outcomes Res. 2021;13:121-133. Published 2021 Feb 10
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). – World Allergy Organ J. 2021 Jan 27;14(2):100509
